110 related articles for article (PubMed ID: 9282239)
1. Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumour markers elaborated by discriminant analysis.
Paone G; De Angelis G; Greco S; Portalone L; De Marchis L; Galluccio G; Taglienti A; Bisetti A; Ameglio F
Respir Med; 1997 Jul; 91(6):361-7. PubMed ID: 9282239
[TBL] [Abstract][Full Text] [Related]
2. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1.
Paone G; De Angelis G; Munno R; Pallotta G; Bigioni D; Saltini C; Bisetti A; Ameglio F
Eur Respir J; 1995 Jul; 8(7):1136-40. PubMed ID: 7589398
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
4. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis: a preliminary report.
Paone G; De Angelis G; Pallotta G; Giannarelli D; Bisetti A; Pigorini F; Ameglio F
Q J Nucl Med; 1995 Jun; 39(2):140-3. PubMed ID: 8574809
[TBL] [Abstract][Full Text] [Related]
6. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
7. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Massaron S; Cataldo I; Oldani S; Iurlo A; Caldiera S; Bombardieri E
Int J Biol Markers; 1999; 14(2):92-8. PubMed ID: 10399628
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
9. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis.
Paone G; De Angelis G; Greco S; Fiorucci F; Bisetti A; Ameglio F
J Cancer Res Clin Oncol; 1996; 122(8):499-503. PubMed ID: 8698751
[TBL] [Abstract][Full Text] [Related]
11. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors.
Paone G; De Angelis G; Portalone L; Greco S; Giosué S; Taglienti A; Bisetti A; Ameglio F
Br J Cancer; 1997; 75(3):448-50. PubMed ID: 9020496
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
[TBL] [Abstract][Full Text] [Related]
13. Clinical tumour markers in lung cancer.
Niklinski J; Furman M
Eur J Cancer Prev; 1995 Apr; 4(2):129-38. PubMed ID: 7539317
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer.
Bates J; Rutherford R; Divilly M; Finn J; Grimes H; O'Muircheartaigh I; Gilmartin JJ
Eur Respir J; 1997 Nov; 10(11):2535-8. PubMed ID: 9426091
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung].
De Angelis G; De Marinis F; Bigioni D; Migliorino MR; Alma MG; Pigorini F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445
[No Abstract] [Full Text] [Related]
16. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of nonsmall cell lung cancer.
Dong Y; Zheng X; Yang Z; Sun M; Zhang G; An X; Pan L; Zhang S
J Cancer Res Ther; 2016 Oct; 12(Supplement):34-36. PubMed ID: 27721249
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
18. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
19. Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer.
Nutini S; Cappelli G; Benucci A; Catalani C; Nozzoli F
Int J Biol Markers; 1990; 5(4):198-202. PubMed ID: 1965544
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer.
Bergman B; Brezicka FT; Engström CP; Larsson S
Eur J Cancer; 1993; 29A(2):198-202. PubMed ID: 8380696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]